Open label trial of adjuvant immunotherapy with Dzherelo, Svitanok and Lizorm, in MDR-TB, XDR-TB and TB/HIV co-infected patients receiving anti-tuberculosis therapy under DOT
Open label trial of anti-tuberculosis therapy (ATT) combined with oral immunomodulators derived from medicinal plants, Dzherelo, Svitanok, and Lizorm, was conducted in a representative group of 14 Ukrainian patients

